KR100748299B1 - 아졸 화합물의 수용성 프로드럭 - Google Patents

아졸 화합물의 수용성 프로드럭 Download PDF

Info

Publication number
KR100748299B1
KR100748299B1 KR1020027009320A KR20027009320A KR100748299B1 KR 100748299 B1 KR100748299 B1 KR 100748299B1 KR 1020027009320 A KR1020027009320 A KR 1020027009320A KR 20027009320 A KR20027009320 A KR 20027009320A KR 100748299 B1 KR100748299 B1 KR 100748299B1
Authority
KR
South Korea
Prior art keywords
formula
compound
hydrogen
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027009320A
Other languages
English (en)
Korean (ko)
Other versions
KR20020070492A (ko
Inventor
야스쯔꾸 우에다
존 디. 마티스켈라
저지 고릭
토마스 더블유. 휴다이마
충-핀 첸
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20020070492A publication Critical patent/KR20020070492A/ko
Application granted granted Critical
Publication of KR100748299B1 publication Critical patent/KR100748299B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polymerization Catalysts (AREA)
KR1020027009320A 2000-01-20 2001-01-16 아졸 화합물의 수용성 프로드럭 Expired - Lifetime KR100748299B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US60/177,169 2000-01-20
US24996900P 2000-11-20 2000-11-20
US60/249,969 2000-11-20

Publications (2)

Publication Number Publication Date
KR20020070492A KR20020070492A (ko) 2002-09-09
KR100748299B1 true KR100748299B1 (ko) 2007-08-09

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009320A Expired - Lifetime KR100748299B1 (ko) 2000-01-20 2001-01-16 아졸 화합물의 수용성 프로드럭

Country Status (22)

Country Link
US (1) US6362172B2 (https=)
EP (1) EP1284737B1 (https=)
JP (1) JP3766804B2 (https=)
KR (1) KR100748299B1 (https=)
CN (1) CN1178665C (https=)
AT (1) ATE300946T1 (https=)
AU (1) AU782177C (https=)
BR (1) BR0107618A (https=)
CA (1) CA2397734C (https=)
CZ (1) CZ20022822A3 (https=)
DE (1) DE60112433T2 (https=)
DK (1) DK1284737T5 (https=)
ES (1) ES2247131T3 (https=)
HU (1) HU229226B1 (https=)
IL (2) IL150798A0 (https=)
MX (1) MXPA02007120A (https=)
NO (1) NO330352B1 (https=)
NZ (1) NZ519354A (https=)
PL (1) PL206024B1 (https=)
PT (1) PT1284737E (https=)
RU (1) RU2266909C2 (https=)
WO (1) WO2001052852A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7803949B2 (en) * 2005-12-20 2010-09-28 Eisai R&D Management Co., Ltd. Process for preparation of water-soluble azole prodrugs
WO2007092580A2 (en) * 2006-02-08 2007-08-16 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
JP5058150B2 (ja) 2006-02-22 2012-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化医薬組成物
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
EP2636409A1 (en) 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
CN103857440B (zh) 2011-06-22 2018-09-25 维奥姆生物科学有限公司 基于缀合物的抗真菌和抗细菌前药
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2013109998A1 (en) 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2839835B1 (en) * 2012-04-20 2016-12-21 Eisai R&D Management Co., Ltd. Encapsulated formulation
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
EA201691534A1 (ru) 2014-01-29 2016-12-30 Вайоми Байосайенсиз Пвт. Лтд. Лечение устойчивых угрей
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
EP3328819B1 (en) * 2015-07-28 2020-04-01 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compounds prodrugs and their uses
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639577A1 (en) * 1993-08-17 1995-02-22 Bristol-Myers Squibb Company Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents
EP0747385A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company Prodrugs of paclitaxel derivatives
WO1997028169A1 (en) * 1996-02-02 1997-08-07 Pfizer Research And Development Company, N.V./S.A. Triazole derivatives useful in therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
MX9308012A (es) 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
IL112081A (en) 1993-12-21 2001-08-26 Schering Plough Corp Tetrahydrofuran derivatives, their preparation and antifungal pharmaceutical compositions containing them
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
ES2141329T3 (es) 1994-01-24 2000-03-16 Janssen Pharmaceutica Nv Antifungicos azolicos solubles en agua.
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
DE69912250T2 (de) 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU1915500A (en) * 1998-11-20 2000-06-13 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639577A1 (en) * 1993-08-17 1995-02-22 Bristol-Myers Squibb Company Phosphonooxymethyl or methylthiomethyl ethers of taxane derivatives as antitumor agents
EP0747385A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company Prodrugs of paclitaxel derivatives
WO1997028169A1 (en) * 1996-02-02 1997-08-07 Pfizer Research And Development Company, N.V./S.A. Triazole derivatives useful in therapy

Also Published As

Publication number Publication date
HU229226B1 (en) 2013-09-30
EP1284737A1 (en) 2003-02-26
DE60112433T2 (de) 2006-05-18
AU2948501A (en) 2001-07-31
EP1284737B1 (en) 2005-08-03
MXPA02007120A (es) 2003-01-28
NZ519354A (en) 2004-05-28
DK1284737T5 (da) 2007-09-24
US20010041691A1 (en) 2001-11-15
DE60112433D1 (de) 2005-09-08
PT1284737E (pt) 2005-11-30
DK1284737T3 (da) 2005-11-28
CZ20022822A3 (cs) 2003-02-12
IL150798A0 (en) 2003-02-12
US6362172B2 (en) 2002-03-26
NO20023468L (no) 2002-07-29
CN1395485A (zh) 2003-02-05
PL206024B1 (pl) 2010-06-30
PL356164A1 (en) 2004-06-14
HUP0204405A3 (en) 2005-02-28
ATE300946T1 (de) 2005-08-15
NO20023468D0 (no) 2002-07-19
JP3766804B2 (ja) 2006-04-19
BR0107618A (pt) 2002-11-12
CA2397734A1 (en) 2001-07-26
CN1178665C (zh) 2004-12-08
NO330352B1 (no) 2011-04-04
KR20020070492A (ko) 2002-09-09
JP2003520235A (ja) 2003-07-02
IL150798A (en) 2006-08-01
CA2397734C (en) 2010-08-17
EP1284737A4 (en) 2003-03-19
AU782177C (en) 2007-10-18
ES2247131T3 (es) 2006-03-01
AU782177B2 (en) 2005-07-07
WO2001052852A1 (en) 2001-07-26
HUP0204405A2 (en) 2003-05-28
RU2266909C2 (ru) 2005-12-27

Similar Documents

Publication Publication Date Title
KR100748299B1 (ko) 아졸 화합물의 수용성 프로드럭
KR100734456B1 (ko) 수용성 아졸 화합물의 개선된 제조 방법
AU2002213317A1 (en) Improved process for water soluble azole compounds
IL187059A (en) Monolysin salts of azole compounds, their preparation and medicinal preparations containing them
US6620934B2 (en) Water soluble prodrugs of azole compounds
ZA200204332B (en) Water soluble prodrugs of azole compounds.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060103

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20060306

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061115

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20070227

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070409

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070710

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070803

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070803

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20080417

FPAY Annual fee payment

Payment date: 20100728

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20100728

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20110727

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20110727

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130726

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130726

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140725

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140725

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150724

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150724

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160722

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160722

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170721

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170721

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180727

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180727

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20190726

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20190726

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20200724

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20200724

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term